Federal Register Notice: FDA has determined that the regulatory review period for Advanced Tissue Sciences’ Dermagraft is 4,050 days for extending a patent which claims that medical device. Dermagraft is indicated for use in treating full-thickness diabetic foot ulcers which are of greater than six-weeks duration and which extend through the dermis, but without tendon, muscle, joint capsule, or bone exposure. The device should be used in conjunction with standard wound care regimens and in patients that have adequate blood supply to the involved foot. To view this notice, click here.
